Mercados españoles cerrados en 2 hrs 52 min

QIAGEN N.V. (QIA.DE)

XETRA - XETRA Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
48,20+0,50 (+1,05%)
A partir del 02:22PM CET. Mercado abierto.

QIAGEN N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
http://www.qiagen.com

Sector(es)Healthcare
SectorDiagnostics & Research
Empleados a tiempo completo5900

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Thierry BernardCEO, MD & Member of Management Board2,41MN/A1965
Dr. Roland SackersCFO, MD & Member of Management Board977,5kN/A1969
Dr. Barthold PieningSr. VP & Head of Global OperationsN/AN/A1958
Mr. John GilardiVP of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Stephany FosterSr. VP & Head of HRN/AN/AN/A
Dr. Thomas SchweinsSr. VP of Life Science Bus. AreaN/AN/AN/A
Dr. Thomas TheuringerSr. Director & Head of External CommunicationsN/AN/AN/A
Mr. Jean-Pascal ViolaSr. VP, Head of Molecular Diagnostics Bus. Area & Corp. Bus. Devel.N/AN/AN/A
Dr. Jonathan G. Sheldon Ph.D.Sr. VP of Qiagen Digital Insights Bus. AreaN/AN/A1972
Mr. Thomas NeidertVP of Global TreasuryN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2020 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Gobierno corporativo

El ISS Governance QualityScore de QIAGEN N.V., a día 1 de julio de 2021, es 4. Las puntuaciones base son Auditoría: 5; Tablero: 3; Derechos de los accionistas: 9; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.